oxb new logo.png
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
September 18, 2024 07:00 ET | OXB
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene...
OXB.jpg
Oxford Biomedica to host a free webinar showcasing its AAV expertise
August 27, 2024 07:00 ET | Oxford BioMedica plc
Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy...
OXB.jpg
Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
August 08, 2024 07:00 ET | Oxford BioMedica plc
Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene...
OXB.jpg
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
March 05, 2024 07:00 ET | Oxford BioMedica plc
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024...
OXB.jpg
Oxford Biomedica completes acquisition of ABL Europe
January 29, 2024 07:00 ET | Oxford BioMedica plc
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple...
OXB.jpg
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
January 23, 2024 07:00 ET | Oxford BioMedica plc
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...
OXB.jpg
Business Update
December 07, 2023 07:00 ET | Oxford BioMedica plc
Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On...
OXB.jpg
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
December 04, 2023 07:04 ET | Oxford BioMedica plc
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement...
OXB.jpg
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
September 20, 2023 07:46 ET | Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
OXB.jpg
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
September 20, 2023 07:41 ET | Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...